NVP Associates, LLC — 13F Holdings & Portfolio
CIK 1545692 · latest 13F-HR filed 2026-08-07
NVP Associates, LLC manages $328.2M in 13F-reported U.S. long-equity assets across 7 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are MBX (35.93%), AVLN (22.75%), OMDA (16.93%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions, exited 1, added to 3, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
MENLO PARK, CA 94025
$328.2M
Long-equity book
7
Distinct positions
2026-06-30
Filed 2026-08-07
+3 / −1 / ↑3 / ↓0
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- MBX BIOSCIENCES INC$54.2M +84.9%
- OMADA HEALTH INC$23.7M +74.6%
- ZENAS BIOPHARMA INC$10.7M +29.8%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | MBX BIOSCIENCES INC | MBX | 55287L101 | $117.9M | 35.93% | 2,136,335 | SH |
| 2 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $74.7M | 22.75% | 2,268,404 | SH |
| 3 | OMADA HEALTH INC | OMDA | 68170A108 | $55.6M | 16.93% | 2,531,000 | SH |
| 4 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $46.7M | 14.22% | 1,838,482 | SH |
| 5 | SNOWFLAKE INC | SNOW | 833445109 | $29.2M | 8.90% | 114,786 | SH |
| 6 | GROVE COLLABORATIVE HOLD INC | GROV | 39957D201 | $4.0M | 1.23% | 3,225,097 | SH |
| 7 | ONDAS INC | ONDS | 68236H204 | $128.6K | 0.04% | 15,602 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-07 | $328.2M | 7 | 0001545692-26-000009 |
| 2026-03-31 | 2026-05-15 | $176.2M | 5 | 0001545692-26-000005 |
| 2025-12-31 | 2026-02-17 | $255.2M | 6 | 0001545692-26-000002 |
| 2025-09-30 | 2025-11-14 | $166.1M | 5 | 0001545692-25-000005 |